Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Actimab-A (lintuzumab-Ac225)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Actinium

Drug class:

Alpha radiation emitter, CD33-targeted antibody- radioimmunoconjugate

Related drugs:

‹

›

TP53 mutation	Acute Myelogenous Leukemia	TP53 mutation	Acute Myelogenous Leukemia	venetoclax + lintuzumab-Ac225 Sensitive: C3 – Early Trials venetoclax + lintuzumab-Ac225 Sensitive : C3	venetoclax + lintuzumab-Ac225 Sensitive: C3 – Early Trials venetoclax + lintuzumab-Ac225 Sensitive : C3
TP53 mutation	Acute Myelogenous Leukemia	TP53 mutation	Acute Myelogenous Leukemia	lintuzumab-Ac225 Sensitive: C3 – Early Trials lintuzumab-Ac225 Sensitive : C3	lintuzumab-Ac225 Sensitive: C3 – Early Trials lintuzumab-Ac225 Sensitive : C3
CD33 expression	Acute Myelogenous Leukemia	CD33 expression	Acute Myelogenous Leukemia	lintuzumab-Ac225 Sensitive: C3 – Early Trials lintuzumab-Ac225 Sensitive : C3	lintuzumab-Ac225 Sensitive: C3 – Early Trials lintuzumab-Ac225 Sensitive : C3
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	lintuzumab-Ac225 Sensitive: D – Preclinical lintuzumab-Ac225 Sensitive : D	lintuzumab-Ac225 Sensitive: D – Preclinical lintuzumab-Ac225 Sensitive : D